Awareness and utilization of BRCA1/2 testing among U.S. primary care physicians
- PMID: 21146769
- DOI: 10.1016/j.amepre.2010.09.027
Awareness and utilization of BRCA1/2 testing among U.S. primary care physicians
Abstract
Background: Testing for mutations in the breast and ovarian cancer susceptibility genes BRCA1 and BRCA2 (BRCA) has been commercially available since 1996.
Purpose: This study sought to determine, among U.S. primary care physicians, the level of awareness and utilization of BRCA testing and the 2005 U.S. Preventive Services Task Force (USPSTF) recommendations.
Methods: In 2009, data were analyzed on 1500 physician respondents to the 2007 DocStyles national survey (515 family practitioners, 485 internists, 250 pediatricians, and 250 obstetricians/gynecologists).
Results: Overall, 87% of physicians were aware of BRCA testing, and 25% reported having ordered testing for at least one patient in the past year. Ordering tests was most prevalent among obstetricians/gynecologists in practice for more than 10 years, with more affluent patients. Physicians were asked to select indications for BRCA testing from seven different clinical scenarios representing increased (4) or low-risk (3) situations consistent with the USPSTF guidelines. Among ordering physicians (pediatricians excluded), 45% chose at least one low-risk scenario as an indication for BRCA testing. Only 19% correctly selected all of the increased-risk and none of the low-risk scenarios.
Conclusions: A substantial majority of primary care physicians are aware of BRCA testing and many report having ordered at least one test within the past year. A minority, however, appear to consistently recognize the family history patterns identified by the USPSTF as appropriate indications for BRCA evaluation. These results suggest the need to improve providers' knowledge about existing recommendations-particularly in this era of increased BRCA direct-to-consumer marketing.
Copyright © 2011 American Journal of Preventive Medicine. All rights reserved.
Similar articles
-
Genetic testing for breast and ovarian cancer susceptibility: evaluating direct-to-consumer marketing--Atlanta, Denver, Raleigh-Durham, and Seattle, 2003.MMWR Morb Mortal Wkly Rep. 2004 Jul 16;53(27):603-6. MMWR Morb Mortal Wkly Rep. 2004. PMID: 15254451
-
Genetic services have value beyond BRCA1/2 testing.Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):686. doi: 10.1158/1055-9965.EPI-08-1087. Cancer Epidemiol Biomarkers Prev. 2009. PMID: 19208665 No abstract available.
-
Mutations of BRCA genes in hereditary breast and ovarian cancer.J Exp Clin Cancer Res. 2002 Sep;21(3 Suppl):9-12. J Exp Clin Cancer Res. 2002. PMID: 12585647 Review.
-
Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility.Am Fam Physician. 2006 Nov 15;74(10):1759-60. Am Fam Physician. 2006. PMID: 17137007 Review. No abstract available.
-
BRCA testing of breast cancer patients: medical specialists' referral patterns, knowledge and attitudes to genetic testing.Eur J Cancer Care (Engl). 2010 May;19(3):369-76. doi: 10.1111/j.1365-2354.2008.01065.x. Epub 2009 Jul 29. Eur J Cancer Care (Engl). 2010. PMID: 19659662
Cited by
-
Malaysian nurses' knowledge and attitudes regarding BRCA genetic testing.Belitung Nurs J. 2021 Dec 6;7(6):493-499. doi: 10.33546/bnj.1802. eCollection 2021. Belitung Nurs J. 2021. PMID: 37497287 Free PMC article.
-
Testing a deliberative democracy method with citizens of African ancestry to weigh pros and cons of targeted screening for hereditary breast and ovarian cancer risk.Front Public Health. 2022 Nov 8;10:984926. doi: 10.3389/fpubh.2022.984926. eCollection 2022. Front Public Health. 2022. PMID: 36424974 Free PMC article.
-
Evaluation of family history in individuals with heterozygous BRCA pathogenic variants diagnosed with breast or ovarian cancer in a single center in Italy.Mol Genet Genomic Med. 2022 Dec;10(12):e2071. doi: 10.1002/mgg3.2071. Epub 2022 Oct 28. Mol Genet Genomic Med. 2022. PMID: 36307994 Free PMC article.
-
Patient and Clinician Decision Support to Increase Genetic Counseling for Hereditary Breast and Ovarian Cancer Syndrome in Primary Care: A Cluster Randomized Clinical Trial.JAMA Netw Open. 2022 Jul 1;5(7):e2222092. doi: 10.1001/jamanetworkopen.2022.22092. JAMA Netw Open. 2022. PMID: 35849397 Free PMC article. Clinical Trial.
-
An overview of genetic services delivery for hereditary breast cancer.Breast Cancer Res Treat. 2022 Feb;191(3):491-500. doi: 10.1007/s10549-021-06478-z. Epub 2022 Jan 26. Breast Cancer Res Treat. 2022. PMID: 35079980 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
